Seyed Amir Raoufi: The Growing Role of CAC and Lp(a) in Preventive Cardiology
Seyed Amir Raoufi, Interventional Cardiologist, shared a post on LinkedIn:
“1. Patient Profile
Age/Gender: middle age Male/Female.
Comorbidities: Controlled Hypertension (on medication), Non-Diabetic.
Clinical Status: Entirely asymptomatic.
Initial Lab Findings: Mildly elevated LDL-C; otherwise normal metabolic profile.
2. Diagnostic Work-up (Guideline 2026 Approach)
To determine the necessity of Antiplatelet and Statin therapy, the following ‘Gatekeeper’ tests are prioritized:
- Lipoprotein(a) [Lp(a)] Measurement: To assess genetic pro-thrombotic and pro-inflammatory risk.
- Coronary Artery Calcium (CAC) Score: To quantify subclinical atherosclerotic burden (The ‘Power of Zero’ versus Plaque Presence).
3. Management Stratification
Scenario A: Low Genomic and Anatomic Risk
- Criteria: Lp(a) less than 50 mg/dL AND CAC equals 0.
- Antiplatelet: ASA Not Indicated.
- Lipid Management: Statin therapy is optional or conservative. LDL-C Target: less than 100 mg/dL (2.6 mmol/L).
Scenario B: Moderate Anatomic Risk
- Criteria: CAC score 1 – 99.
- Antiplatelet: ASA usually withheld unless other high-risk features are present.
- Lipid Management: Initiate Statin. LDL-C Target: less than 70 mg/dL (1.8 mmol/L).
Scenario C: High Genomic or Anatomic Risk
- Criteria: Lp(a) more than 50 mg/dL OR CAC \ge 100.
- Antiplatelet: Initiate Aspirin (81-100 mg) to mitigate the synergistic risk of thrombosis and plaque rupture (Class IIa).
- Lipid Management: High-intensity Statin. LDL-C Target: less than 55 mg/dL (1.4 mmol/L).
4. Clinical Reasoning (Key Takeaways)
The Synergistic Effect: Elevated Lp(a) acts as a pro-thrombotic modifier.
When Lp(a) is high, even non-obstructive plaques (confirmed by CAC more than 0) are more likely to cause an acute event due to impaired fibrinolysis.
Bleeding versus Ischemic Risk: In primary prevention, Aspirin is reserved for patients where CAC \ge 100 or elevated Lp(a) tips the balance in favor of ischemic protection over the risk of GI bleeding.
2026 Shift: We treat the Plaque Biology and Genetic Predisposition rather than just the LDL-C number.
Clinical Pearl: In 2026, the CAC score is no longer just “nice to have”; it is the decisive tool for preventing over-treatment with Aspirin in low-risk individuals and ensuring aggressive protection for those with subclinical disease.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome